Maladies rares de l’hypophyse

1: Illouz F, Chanson P, Sonnet E, Brue T, Ferriere A, Raffin Sanson ML,

Vantyghem MC, Raverot G, Munier M, Rodien P, Briet C. Somatostatin receptor

ligands induce TSH deficiency in thyrotropin-secreting pituitary adenoma. Eur J

Endocrinol. 2021 Jan;184(1):1-8. doi: 10.1530/EJE-20-0484. PMID: 33112257.

 

2: Chevalier B, Odou MF, Demonchy J, Cardot-Bauters C, Vantyghem MC. Multiple

Endocrine Neoplasia Type 4: Novel CDNK1B variant and immune anomalies. Ann

Endocrinol (Paris). 2020 Jun;81(2-3):124-125. doi: 10.1016/j.ando.2020.04.002.

Epub 2020 Apr 10. PMID: 32386678.

 

3: Fleseriu M, Petersenn S, Biller BMK, Kadioglu P, De Block C, T’Sjoen G,

Vantyghem MC, Tauchmanova L, Wojna J, Roughton M, Lacroix A, Newell-Price J.

Long-term efficacy and safety of once-monthly pasireotide in Cushing’s disease:

A Phase III extension study. Clin Endocrinol (Oxf). 2019 Dec;91(6):776-785. doi:

10.1111/cen.14081. Epub 2019 Oct 1. PMID: 31465533; PMCID: PMC6899900.

 

4: Lacroix A, Gu F, Gallardo W, Pivonello R, Yu Y, Witek P, Boscaro M, Salvatori

R, Yamada M, Tauchmanova L, Roughton M, Ravichandran S, Petersenn S, Biller BMK,

Newell-Price J; Pasireotide G2304 Study Group. Efficacy and safety of once-

monthly pasireotide in Cushing’s disease: a 12 month clinical trial. Lancet

Diabetes Endocrinol. 2018 Jan;6(1):17-26. doi: 10.1016/S2213-8587(17)30326-1.

Epub 2017 Oct 12. Erratum in: Lancet Diabetes Endocrinol. 2018 Jan;6(1):e1.

PMID: 29032078.

 

5: Chanson P, Raverot G, Castinetti F, Cortet-Rudelli C, Galland F, Salenave S;

French Endocrinology Society non-functioning pituitary adenoma work-group.

Management of clinically non-functioning pituitary adenoma. Ann Endocrinol

(Paris). 2015 Jul;76(3):239-47. doi: 10.1016/j.ando.2015.04.002. Epub 2015 Jun

1. PMID: 26072284.

 

6: Galland F, Vantyghem MC, Cazabat L, Boulin A, Cotton F, Bonneville JF,

Jouanneau E, Vidal-Trécan G, Chanson P. Management of nonfunctioning pituitary

incidentaloma. Ann Endocrinol (Paris). 2015 Jul;76(3):191-200. doi:

10.1016/j.ando.2015.04.004. Epub 2015 Jun 6. PMID: 26054868.

 

7: Nozières C, Zhang CX, Buffet A, Dupasquier S, Vargas-Poussou R, Guillaud-

Bataille M, Cordier-Bussat M, Ruszniewski P, Christin-Maitre S, Murat A,

Groussin L, Vezzosi D, Cardot-Bauters C, Hervieu V, Joly MO, Giraud S, Odou MF,

Gimenez-Roqueplo AP, Goudet P, Borson-Chazot F, Calender A; Groupe français des

tumeurs endocrines (GTE). p.Ala541Thr variant of MEN1 gene: a non deleterious

polymorphism or a pathogenic mutation? Ann Endocrinol (Paris). 2014

Jul;75(3):133-40. doi: 10.1016/j.ando.2014.05.003. Epub 2014 Jul 2. PMID:

24997771.

 

8: Castinetti F, Guignat L, Giraud P, Muller M, Kamenicky P, Drui D, Caron P,

Luca F, Donadille B, Vantyghem MC, Bihan H, Delemer B, Raverot G, Motte E,

Philippon M, Morange I, Conte-Devolx B, Quinquis L, Martinie M, Vezzosi D, Le

Bras M, Baudry C, Christin-Maitre S, Goichot B, Chanson P, Young J, Chabre O,

Tabarin A, Bertherat J, Brue T. Ketoconazole in Cushing’s disease: is it worth a

try? J Clin Endocrinol Metab. 2014 May;99(5):1623-30. doi: 10.1210/jc.2013-3628.

Epub 2014 Jan 28. PMID: 24471573.

 

9: Leroy C, Karrouz W, Douillard C, Do Cao C, Cortet C, Wémeau JL, Vantyghem MC.

Diabetes insipidus. Ann Endocrinol (Paris). 2013 Dec;74(5-6):496-507. doi:

10.1016/j.ando.2013.10.002. Epub 2013 Nov 25. PMID: 24286605.

 

10: Vantyghem MC, Balavoine AS, Wémeau JL, Douillard C. Hyponatremia and

antidiuresis syndrome. Ann Endocrinol (Paris). 2011 Dec;72(6):500-12. doi:

10.1016/j.ando.2011.10.001. Epub 2011 Nov 25. PMID: 22119069.

 

11: Mouton F, Faivre-Defrance F, Cortet-Rudelli C, Assaker R, Soto-Ares G,

Defoort-Dhellemmes S, Blond S, Wemeau JL, Vantyghem MC. TSH-secreting adenoma

improved with cabergoline. Ann Endocrinol (Paris). 2008 Jun;69(3):244-8. doi:

10.1016/j.ando.2008.02.001. Epub 2008 May 19. PMID: 18486933.

 

12: Vantyghem MC, Douillard C, Evrard A, Lefebvre J. Relations entre l’axe

corticotrope et l’arginine vasopressine en pathologie endocrinienne

[Relationship between corticotropin and arginine vasopressin in endocrine

diseases]. Presse Med. 1999 Jun 5;28(20):1085-90. French. PMID: 10394380.

 

13: Evrard A, Hober C, Racadot A, Lefebvre J, Vantyghem MC. Hormone

natriurétique auriculaire et fonctions endocrines [Atrial natriuretic hormone

and endocrine functions]. Ann Biol Clin (Paris). 1999 Mar-Apr;57(2):149-55.

French. PMID: 10210741.

 

14: Vantyghem MC, Cortet C, Bauters C, Gevaert MH, Dewailly D, Lefebvre J,

Mazzucca M. Immunohistochemical detection of glycoprotein hormone alpha subunit

in somatoprolactinic and pure somatotroph adenomas. J Endocrinol Invest. 1998

Jul-Aug;21(7):434-40. doi: 10.1007/BF03347322. PMID: 9766257.

 

15: Giraud S, Zhang CX, Serova-Sinilnikova O, Wautot V, Salandre J, Buisson N,

Waterlot C, Bauters C, Porchet N, Aubert JP, Emy P, Cadiot G, Delemer B, Chabre

O, Niccoli P, Leprat F, Duron F, Emperauger B, Cougard P, Goudet P, Sarfati E,

Riou JP, Guichard S, Rodier M, Meyrier A, Caron P, Vantyghem MC, Assayag M, Peix

JL, Pugeat M, Rohmer V, Vallotton M, Lenoir G, Gaudray P, Proye C, Conte-Devolx

B, Chanson P, Shugart YY, Goldgar D, Murat A, Calender A. Germ-line mutation

analysis in patients with multiple endocrine neoplasia type 1 and related

disorders. Am J Hum Genet. 1998 Aug;63(2):455-67. doi: 10.1086/301953. PMID:

9683585; PMCID: PMC1377295.

 

16: Cortet-Rudelli C, Coche-Dequeant B, Castelain B, Blond S, Hamon M, Defoort

S, Vantyghem MC, Fossati P, Dewailly D. Radiothérapie hypophysaire. Données

actuelles et perspectives d’avenir [Pituitary radiotherapy. Current data and

future prospects]. Ann Endocrinol (Paris). 1997;58(1):21-9. French. PMID:

9207963.

 

17: Vantyghem MC, Hober C, Lefebvre J. Diabètes insipides congénitaux.

Acquisitions récentes en génétique moléculaire [Congenital diabetes insipidus.

Recent advances in molecular genetics]. Presse Med. 1996 Feb 24;25(7):299-303.

French. PMID: 8685170.

 

18: Decanter C, Hober C, Hamon M, Lafitte JJ, Lefebvre J, Vantyghem MC. Diabète

insipide révélateur d’une métastase hypophysaire d’un carcinome bronchique

[Diabetes insipidus revealing pituitary metastasis of bronchial carcinoma]. Ann

Endocrinol (Paris). 1996;57(5):411-7. French. PMID: 8991105.

 

19: Evrard A, Vantyghem MC, Huglo D, Hober C, Marchandise X, Mazzuca M, Lefebvre

1. Adénome gonadotrope fixant un analogue de la somatostatine marquée. Absence

de corrélation avec l’efficacité thérapeutique [Gonadotropi adenoma linking

labeled somatostatin analogs. Lack of relationship with therapeutic effect]. Ann

Endocrinol (Paris). 1996;57(3):209-14. French. PMID: 8949416.

 

20: Prévost G, Vantyghem MC, Hober C, Evrard A, Huglo D, Bonneville L, Epelbaum

J, Lefebvre J. Les adénomes thyréotropes: revue de la littérature. A propos de

deux cas [Thyreotropic adenoma: review of the literature. Apropos of 2 cases].

Ann Endocrinol (Paris). 1996;57(3):194-202. French. PMID: 8949414.

 

21: Le Tourneau T, Tison E, Auffray JL, Hachulla E, Vantyghem MC, Millaire A,

Ducloux G. Syndrome de sécrétion inappropriée d’ADH et hyperéosinophilie au

cours d’une maladie de Horton avec sténoses des artères sous-clavières

[Inappropriate ADH secretion syndrome and hypereosinophilia in Horton disease

with stenosis of the subclavian arteries]. Rev Med Interne. 1994

Apr;15(4):273-8. French. doi: 10.1016/s0248-8663(94)80032-4. PMID: 8059148.

 

1. Lasolle H, Elsensohn MH, Wierinckx A, Alix E, Bonnefille C, Vasiljevic A,

Cortet C, Decoudier B, Sturm N, Gaillard S, Ferrière A, Roy P, Jouanneau E,

Bertolino P, Bardel C, Sanlaville D, Raverot G. Chromosomal instability in the

prediction of pituitary neuroendocrine tumors prognosis. Acta Neuropathol

Commun. 2020 Nov 10;8(1):190. doi: 10.1186/s40478-020-01067-5. PMID: 33168091;

PMCID: PMC7653703.

 

23: Duhamel C, Ilie MD, Salle H, Nassouri AS, Gaillard S, Deluche E, Assaker R,

Mortier L, Cortet C, Raverot G. Immunotherapy in Corticotroph and Lactotroph

Aggressive Tumors and Carcinomas: Two Case Reports and a Review of the

Literature. J Pers Med. 2020 Aug 13;10(3):88. doi: 10.3390/jpm10030088. PMID:

32823651; PMCID: PMC7563495.

 

24: Allard L, Albarel F, Bertherat J, Caron PJ, Cortet C, Courtillot C, Delemer

B, Jublanc C, Maiter D, Nunes ML, Raverot G, Sarfati J, Salenave S, Corruble E,

Choucha W, Chanson P. Efficacy and safety of dopamine agonists in patients

treated with antipsychotics and presenting a macroprolactinoma. Eur J

Endocrinol. 2020 Aug 1;183(2):221-231. doi: 10.1530/EJE-20-0125. PMID: 32583656.

 

25: Castinetti F, Albarel F, Archambeaud F, Bertherat J, Bouillet B, Buffier P,

Briet C, Cariou B, Caron P, Chabre O, Chanson P, Cortet C, Do Cao C, Drui D,

Haissaguerre M, Hescot S, Illouz F, Kuhn E, Lahlou N, Merlen E, Raverot V, Smati

S, Verges B, Borson-Chazot F. French Endocrine Society Guidance on endocrine

side effects of immunotherapy. Endocr Relat Cancer. 2019 Feb;26(2):G1-G18. doi:

10.1530/ERC-18-0320. PMID: 30400055; PMCID: PMC6347286.

 

26: Briet C, Albarel F, Kuhn E, Merlen E, Chanson P, Cortet C. Expert opinion on

pituitary complications in immunotherapy. Ann Endocrinol (Paris). 2018

Oct;79(5):562-568. doi: 10.1016/j.ando.2018.07.008. Epub 2018 Jul 25. PMID:

30126625.

 

27: Castinetti F, Albarel F, Archambeaud F, Bertherat J, Bouillet B, Buffier P,

Briet C, Cariou B, Caron P, Chabre O, Chanson P, Cortet C, Do Cao C, Drui D,

Haissaguerre M, Hescot S, Illouz F, Kuhn E, Lahlou N, Merlen E, Raverot V, Smati

S, Verges B, Borson-Chazot F. Endocrine side-effects of new anticancer

therapies: Overall monitoring and conclusions. Ann Endocrinol (Paris). 2018

Oct;79(5):591-595. doi: 10.1016/j.ando.2018.07.005. Epub 2018 Jul 11. PMID:

30056975.

 

28: Young J, Bertherat J, Vantyghem MC, Chabre O, Senoussi S, Chadarevian R,

Castinetti F; Compassionalte use Programme. Hepatic safety of ketoconazole in

Cushing’s syndrome: results of a Compassionate Use Programme in France. Eur J

Endocrinol. 2018 May;178(5):447-458. doi: 10.1530/EJE-17-0886. Epub 2018 Feb 22.

PMID: 29472378.

 

29: Reznik Y, Barat P, Bertherat J, Bouvattier C, Castinetti F, Chabre O, Chanson

P, Cortet C, Delemer B, Goichot B, Gruson D, Guignat L, Proust-Lemoine E, Sanson

MR, Reynaud R, Boustani DS, Simon D, Tabarin A, Zenaty D. SFE/SFEDP adrenal

insufficiency French consensus: Introduction and handbook. Ann Endocrinol

(Paris). 2018 Feb;79(1):1-22. doi: 10.1016/j.ando.2017.12.001. Epub 2018 Jan 12.

PMID: 29338844.

 

30: McCormack A, Dekkers OM, Petersenn S, Popovic V, Trouillas J, Raverot G,

Burman P; ESE survey collaborators. Treatment of aggressive pituitary tumours

and carcinomas: results of a European Society of Endocrinology (ESE) survey

1. Eur J Endocrinol. 2018 Mar;178(3):265-276. doi: 10.1530/EJE-17-0933. Epub

2018 Jan 12. PMID: 29330228.

 

31: Cortet C, Barat P, Zenaty D, Guignat L, Chanson P. Group 5: Acute adrenal

insufficiency in adults and pediatric patients. Ann Endocrinol (Paris). 2017

Dec;78(6):535-543. doi: 10.1016/j.ando.2017.10.008. Epub 2017 Nov 23. PMID:

29174201.

 

32: Lasolle H, Cortet C, Castinetti F, Cloix L, Caron P, Delemer B, Desailloud

R, Jublanc C, Lebrun-Frenay C, Sadoul JL, Taillandier L, Batisse-Lignier M,

Bonnet F, Bourcigaux N, Bresson D, Chabre O, Chanson P, Garcia C, Haissaguerre

M, Reznik Y, Borot S, Villa C, Vasiljevic A, Gaillard S, Jouanneau E, Assié G,

Raverot G. Temozolomide treatment can improve overall survival in aggressive

pituitary tumors and pituitary carcinomas. Eur J Endocrinol. 2017

Jun;176(6):769-777. doi: 10.1530/EJE-16-0979. PMID: 28432119.

 

33: Ferriere A, Cortet C, Chanson P, Delemer B, Caron P, Chabre O, Reznik Y,

Bertherat J, Rohmer V, Briet C, Raingeard I, Castinetti F, Beckers A, Vroonen L,

Maiter D, Cephise-Velayoudom FL, Nunes ML, Haissaguerre M, Tabarin A.

Cabergoline for Cushing’s disease: a large retrospective multicenter study. Eur

J Endocrinol. 2017 Mar;176(3):305-314. doi: 10.1530/EJE-16-0662. Epub 2016 Dec

1. PMID: 28007845.

 

34: Giustina A, Bevan JS, Bronstein MD, Casanueva FF, Chanson P, Petersenn S,

Thanh XM, Sert C, Houchard A, Guillemin I, Melmed S; SAGIT Investigator Group.

SAGIT®: clinician-reported outcome instrument for managing acromegaly in

clinical practice–development and results from a pilot study. Pituitary. 2016

Feb;19(1):39-49. doi: 10.1007/s11102-015-0681-2. PMID: 26377024; PMCID:

PMC4710645.

 

35: Schopohl J, Gu F, Rubens R, Van Gaal L, Bertherat J, Ligueros-Saylan M,

Trovato A, Hughes G, Salgado LR, Boscaro M, Pivonello R; Pasireotide B2305 Study

Group. Pasireotide can induce sustained decreases in urinary cortisol and

provide clinical benefit in patients with Cushing’s disease: results from an

open-ended, open-label extension trial. Pituitary. 2015 Oct;18(5):604-12. doi:

10.1007/s11102-014-0618-1. PMID: 25537481; PMCID: PMC4560758.

 

36: Pivonello R, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M,

Trovato A, Hughes G, Salgado LR, Lacroix A, Schopohl J, Biller BM; Pasireotide

B2305 Study Group. Pasireotide treatment significantly improves clinical signs

and symptoms in patients with Cushing’s disease: results from a Phase III study.

Clin Endocrinol (Oxf). 2014 Sep;81(3):408-17. doi: 10.1111/cen.12431. Epub 2014

Mar 27. PMID: 24533697.

 

37: Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, Sen K, Salgado

LR, Colao A, Biller BM; Pasireotide B2305 Study Group. High variability in

baseline urinary free cortisol values in patients with Cushing’s disease. Clin

Endocrinol (Oxf). 2014 Feb;80(2):261-9. doi: 10.1111/cen.12259.

 

38: Colao A, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M,

Schoenherr U, Mills D, Salgado LR, Biller BM; Pasireotide B2305 Study Group. A

12-month phase 3 study of pasireotide in Cushing’s disease. N Engl J Med. 2012

Mar 8;366(10):914-24. doi: 10.1056/NEJMoa1105743. Erratum in: N Engl J Med. 2012

Aug 23;367(8):780. PMID: 22397653.

 

39: Fieffe S, Morange I, Petrossians P, Chanson P, Rohmer V, Cortet C, Borson-

Chazot F, Brue T, Delemer B; French Acromegaly Registry. Diabetes in acromegaly,

prevalence, risk factors, and evolution: data from the French Acromegaly

Registry. Eur J Endocrinol. 2011 Jun;164(6):877-84.

 

40: Gatta B, Chabre O, Cortet C, Martinie M, Corcuff JB, Roger P, Tabarin A.

Reevaluation of the combined dexamethasone suppression-corticotropin-releasing

hormone test for differentiation of mild cushing’s disease from pseudo-Cushing’s

syndrome. J Clin Endocrinol Metab. 2007 Nov;92(11):4290-3.

 

41: Cortet B, Cortet C, Blanckaert F, d’Herbomez M, Marchandise X, Wémeau J-L,

Decoulx M, Dewailly D. Quantitative ultrasound of bone and markers of bone

turnover in Cushing’s syndrome. Osteoporos Int. 2001;12(2):117-23.

 

42: Chanson P, Boerlin V, Ajzenberg C, Bachelot Y, Benito P, Bringer J, Caron P,

Charbonnel B, Cortet C, Delemer B, Escobar-Jiménez F, Foubert L, Gaztambide S,

Jockenhoevel F, Kuhn JM, Leclere J, Lorcy Y, Perlemuter L, Prestele H, Roger P,

Rohmer V, Santen R, Sassolas G, Scherbaum WA, Schopohl J, Torres E, Varela C,

Villamil F, Webb SM. Comparison of octreotide acetate LAR and lanreotide SR in

patients with acromegaly. Clin Endocrinol (Oxf). 2000 Nov;53(5):577-86.

 

43: Waterlot C, Porchet N, Bauters C, Decoulx M, Wémeau JL, Proye C, Degand PM,

Aubert JP, Cortet C, Dewailly D. Type 1 multiple endocrine neoplasia (MEN1):

contribution of genetic analysis to the screening and follow-up of a large

French kindred. Clin Endocrinol (Oxf). 1999 Jul;51(1):101-7.

 

44 Jannin A, Merlen E, Do Cao C, Penel N. L’hypophysite auto-immune,

complication des nouvelles immunothérapies anticancéreuses [Autoimmune

hypophysitis associated with new anti-cancer immunotherapies]. Bull Cancer. 2018

Mar;105(3):275-280. French.

 

45 .Growth hormone replacement therapy in patients with traumatic brain injury. Moreau OK, Cortet-Rudelli C, Yollin E,Merlen E, Daveluy W, Rousseaux M.J Neurotrauma. 2013 Jun 1;30(11):998-1006. doi: 10.1089/neu.2012.2705. Epub 2013 Jun 5.PMID: 23323993

 

46 .asting pituitary hormone deficiency after traumatic brain injury.Kozlowski Moreau O, Yollin E,Merlen E, Daveluy W, Rousseaux M.J Neurotrauma. 2012 Jan 1;29(1):81-9.

 

47 . [Revelation of a polymicrocystic ovary syndrome after one month’s treatment by pulsatile GnRH in a patient presenting with functional hypothalamic amenorrhea].Reyss AC,Merlen E, Demerle C, Dewailly D.Gynecol Obstet Fertil. 2003 Dec;31(12):1039-42.